NCT05597345View on ClinicalTrials.gov

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 21, 2023

Primary Completion Date

October 29, 2024

Study Completion Date

December 31, 2025

Conditions
Smoldering Multiple Myeloma
Interventions
DRUG

Selinexor

Low-dose Selinexor for the Treatment of Intermediate to High-Risk Smoldering Multiple Myeloma

Trial Locations (1)

14642

RECRUITING

University of Rochester, Rochester

Sponsors
All Listed Sponsors
collaborator

Karyopharm Therapeutics Inc

INDUSTRY

lead

University of Rochester

OTHER